Pharmacokinetics in IBD: Ready for Prime Time?

Author(s): Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul

Volume 15, Issue 11, 2014

Page: [1049 - 1055] Pages: 7

DOI: 10.2174/1389450115666140829153509

Price: $65

Abstract

This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].

Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy